MorphoSys AG MOR released topline results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis.
Myelofibrosis causes extensive scarring in the bone marrow, leading to severe anemia. Bone marrow…

#morphosysag#pelabresib#bet#jak#tss#morphosys#newdrugapplication#fda